Goldman Sachs’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.8M | Sell |
|
|||||
|
2025
Q1 | $4.17M | Buy |
|
|||||
|
2024
Q4 | $2.95M | Buy |
|
|||||
|
2024
Q3 | $3.11M | Buy |
|
|||||
|
2024
Q2 | $1.54M | Buy |
|
|||||
|
2024
Q1 | $304K | Sell |
|
|||||
|
2023
Q4 | $314K | Buy |
|
|||||
|
2023
Q3 | $242K | Sell |
|
|||||
|
2023
Q2 | $557K | Sell |
|
|||||
|
2023
Q1 | $907K | Buy |
|
|||||
|
2022
Q3 | – | Sell |
|
|||||
|
2022
Q2 | $1.06M | Buy |
|
|||||
|
2022
Q1 | $1.57M | Sell |
|
|||||
|
2021
Q4 | $1.9M | Buy |
|
|||||
|
2021
Q3 | $155K | Buy |
|
|||||
|
2021
Q2 | $83K | Sell |
|
|||||
|
2021
Q1 | $108K | Buy |
|
|||||
|
2020
Q2 | – | Sell |
|
|||||
|
2020
Q1 | $769K | Buy |
|